American Well Corp
No enriched coverage for $AMWL in the last 7 days.
No SEC Form 4 filings for $AMWL in the last 30 days.
See all $AMWL insider activity →American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
Analyst estimates cited by FactSet show American Well Corp’s 12-month average price target increased from $8.50 to $11.58. The range is $7.50 to $16. Based on the Aug. 4 close, the target implies about 11% upside. The consensus rating remains “Hold” (1 Buy, 7 Hold, 0 Sell) across 8 analysts.
Recent AMWL coverage spans market movers, earnings and corporate actions.
Guidance raises and a Defense Health Agency sole-source intent are likely to support near-term sentiment, but Q3 EBITDA loss guidance and churn keep risk elevated.
The trade is profitability improvement versus declining revenue, with Q3 guidance setting the near-term ceiling.
The article is a sell-side target revision story, not a fundamental company disclosure. It can still move near-term sentiment and positioning if traders treat PT changes as a proxy for improving outlook.
Guidance raise plus improving adjusted EBITDA trajectory suggests improving operating leverage, but GAAP remains loss-making.
Board class rebalancing is administrative and explicitly not due to disagreements, so near-term fundamentals should be largely unchanged.
alphai scores every news story that mentions AMWL with an AI model for sentiment and relevance, and aggregates insider trades from American Well Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.
6 min readBiotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readAnalyst estimates cited by FactSet show American Well Corp’s 12-month average price target increased from $8.50 to $11.58. The range is $7.50 to $16. Based on the Aug. 4 close, the target implies about 11% upside. The consensus rating remains “Hold” (1 Buy, 7 Hold, 0 Sell) across 8 analysts.
1 min readAmerican Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026
4 min readAmerican Well Corp (AMWL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001393584 false 0001393584 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08,
2 min readBiotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.
7 min readBiotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.
5 min readAmerican Well Corp (AMWL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001393584 0001393584 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16,
2 min readHIRSCHHORN MARK (Chief Financial Officer) sold 10,761 shares of American Well Corp (AMWL) at $9.74 ($0.10M total) on 2026-06-01.
1 min readGotlib Phyllis (President, International) sold 3,573 shares of American Well Corp (AMWL) at $9.74 on 2026-06-01.
2 min read
